A method for preparing H9 subtype avian influenza virus HA1 protein presented by biomimetic vesicles of Escherichia coli and its application
By constructing the O78 serotype Escherichia coli defect strain ΔtolA-ΔaraD and utilizing high-pressure homogenization technology and ClyA-HA1 fusion protein expression, the problem of weak immune efficacy of existing vaccines in mixed infections of H9N2 subtype avian influenza virus and O78 serotype avian Escherichia coli was solved, achieving highly effective bivalent vaccine protection.
Patent Information
- Application Number
- CN202411499731.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-25
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-10-25
AI Technical Summary
Existing vaccines have weak immune effects when dealing with mixed infections of H9N2 subtype avian influenza virus and O78 serotype avian coliform infection, and traditional vector systems have the problem of unsatisfactory cross-protection.
We constructed a ΔtolA-ΔaraD strain of O78 serotype Escherichia coli and achieved HA1 protein presentation on the surface of biomimetic vesicles through L-arabinose induction and high-pressure homogenization. We then used a fusion protein expression of ClyA protein and HA1 protein via a linker to improve vesicle yield and soluble expression of HA1 protein.
It significantly improved the immune protection against H9N2 subtype avian influenza virus and O78 serotype Escherichia coli, enhanced mucosal and humoral immune responses, reduced bacterial load in chickens, alleviated inflammation, and provided effective bivalent vaccine protection.
Smart Images

Figure CN119331108B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to a method for preparing a high-yield biomimetic vesicle stably presenting H9N2 subtype avian influenza virus (AIV) HA1 protein derived from O78 serotype Escherichia coli and its application in combating H9 subtype avian influenza and avian colibacillosis. Background Technology
[0002] In intensive poultry farms, mixed infections with multiple pathogens are common, resulting in significant economic losses. The H9N2 subtype of avian influenza virus (AIV) is one of the most prevalent pathogens in poultry in my country. While it has low pathogenicity when present alone and usually does not cause direct death, it is directly related to many production losses in practice. Avian pathogenic E. coli (APEC), one of the most common bacterial pathogens in poultry, often co-infects with the H9N2 subtype of AIV, producing a synergistic effect that leads to increased poultry mortality, decreased production performance, and the risk of foodborne transmission to humans.
[0003] Vaccination is currently one of the main strategies for controlling avian influenza and avian colibacillosis. Subunit vaccines, as a novel type of vaccine, stimulate an immune response by presenting specific antigenic components of the pathogen, offering advantages such as higher safety and simpler production compared to traditional vaccines. However, subunit vaccines typically have weak immunogenicity, necessitating effective vector systems to enhance their immunogenicity. In recent years, research on outer membrane vesicles (OMVs) as subunit vaccine vectors has gained increasing attention. Among them, E. coli OMVs have become a research hotspot due to their ease of preparation, low cost, and high controllability. Recent studies have shown that heterologous proteins produced in the outer membrane or periplasm can be targeted to OMVs. Furthermore, this targeting process can also be achieved by fusing heterologous proteins with vesicle-associated proteins, thus opening up possibilities for displaying exogenous proteins using OMVs as vectors. E. coli's ClyA, as a membrane-anchoring protein, is transported to OMVs through the bacteria's own regulatory mechanisms. However, because high levels of ClyA cannot be localized to the outer membrane, OMVs have limited ability to present exogenous proteins, which greatly limits the efficiency of ClyA anchoring to the outer membrane to deliver antigens.
[0004] Traditional vaccines have limitations in addressing the diversity and variability of pathogens, and antibiotic overuse has led to bacterial resistance. APEC vaccines contain numerous serotypes, with O78 being one of the most common in China. However, due to the less-than-ideal cross-protection between different APEC serotypes, existing engineered E. coli OMVs expressing exogenous proteins can only generate an immune response against exogenous antigens. Therefore, developing a bivalent vaccine that simultaneously targets both H9N2 AIV and O78 APEC serotypes has become an urgent scientific challenge and a practical necessity. Summary of the Invention
[0005] To address the aforementioned issues, this invention improves biomimetic vesicle production by constructing a defective strain of O78 serotype Escherichia coli ΔtolA-ΔaraD. Through L-arabinose induction and high-pressure homogenization, HA1 protein is presented on the surface of the biomimetic vesicles, and its effectiveness as an immunogen in protecting chickens from infection by H9N2 subtype avian influenza virus and O78 serotype Escherichia coli is evaluated.
[0006] The technical solution provided by this invention is as follows:
[0007] A fusion protein, wherein the fusion protein is obtained by linking ClyA protein and HA1 protein together via a linker; the sequences of the ClyA protein, the linker and the HA1 protein are shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3.
[0008] This invention also provides a method for preparing H9 subtype avian influenza virus HA1 protein presented by biomimetic vesicles of *E. coli*. ClyA and H9N2 AIV HA1 protein are tandemly linked via a linker, and the fusion protein is expressed in a vesicle donor. High-pressure homogenization is then used to present the fusion protein ClyA-HA1 onto the surface of the biomimetic vesicle, yielding recombinant biomimetic vesicles (BBVs). The nucleotide sequences of the ClyA protein, linker, and HA1 protein have been codon-optimized for *E. coli*, as shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3.
[0009] SEQ ID NO.1:
[0010] ATGACAGAAATAGTAGCTGACAAGACCGTTGAGGTGGTGAAAAACGCCATCGAAACCGCAGATGGTGCACTCGACCTGTATAACAAGTATCTGGACCAGGTGATTCCGTGGCAGACCTTTGATGAAACCATCAAGGAGCTGAGTCGTTTTAAACAAGAATACAGCCAAGCGGCGTCTGTTCTGGTTGGTGACATCAAGACTTTGCTTATGGATTCGCAAGATAAGTACTTCGAAGCGACGCAAACCGTTTATGAGTGGTGTGGTGTCGCTACCCAGCTGTTGGCGGCATATATTCTGTTATTCGACGAGTACAACGAAAAGAAAGCGAGCGCGCAGAAAGACATTCTGATCAAGGTGCTGGACGACGGCATTACCAAATTGAATGAGGCTCAAAAGTCTTTGTTGGTTTCATCCCAGAGCTTCAACAACGCGTCTGGAAAGTTGCTGGCGCTGGACAGCCAGCTGACCAATGATTTCAGCGAAAAGTCCAGCTATTTCCAGAGCCAAGTGGACAAAATCCGTAAAGAAGCCTACGCAGGCGCGGCCGCGGGTGTTGTAGCCGGTCCGTTTGGTCTGATCATCAGCTACAGCATTGCCGCAGGTGTCGTGGAAGGCAAGCTCATCCCGGAACTGAAGAACAAGCTGAAATCAGTCCAGAATTTCTTTACCACCCTGAGCAATACCGTGAAGCAGGCAAATAAAGATATTGATGCAGCGAAATTAAAGCTCACCACAGAGATCGCGGCGATTGGCGAAATTAAAACCGAGACGGAAACGACCCGTTTTTATGTTGACTACGATGACCTGATGCTGAGCCTGCTTAAGGAGGCGGCTAAAAAAATGATTAACACGTGCAACGAGTACCAGAAGCGCCATGGTAAAAAAACTCTGTTCGAGGTTCCGGAGGTG;
[0011] SEQ ID NO.2:
[0012] GGCTCCGGCTCTGGTGAAGGTTCCGGC;
[0013] SEQ ID NO.3:
[0014] GACAAAATCTGCATTGGTTATCAAAGCACGAACAGCACCGAAACCGTTGATACGCTGACTGAGAACAACGTGCCGGTTACACATGCGAAAGAACTGCTTCACACCGAGCACAACGGCATGCTGTGTGCGACCGGTTTGGGCCACCCGCTCATCCTGGATACGTGCACCATTGAAGGTCTGATCTACGGCAATCCGAGCTGCGACCTGTTGTTGGGTGGACGTGAATGGAGCTATATCGTGGAAAGACCATCCGCGGTTAACGGTCTGTGCTACCCGGGTAACGTGGAGAACCTGGAAGAGCTGCGCAGCCTTTTCAGTTCTGCGTCCTCCTACCAACGTATCCAAATCTTTCCGGATACCATCTGGAATGTGACGTACAGCGGCACCAGCAAGGCGTGTTCGGACAGCTTCTATCGTAGCATGCGTTGGCTGACCCAGAAAAATAACGCCTACCCGATTCAGGATGCTCAATATACCAACAACCAAGAAAAAAACATTCTGTTCATGTGGGGTATTAACCATCCGCCTACTGACACTGCCCAAACGAACCTGTACACCCGTACCGACACCACAACCTCCGTTGCGACCGAGGAGATCAACCGTACCTTTAAACCGTTGATTGGTCCGCGTCCGTTGGTTAATGGTTTACAGGGTCGCATCGATTATTACTGGTCAGTCCTGAAGCCGGGTCAGACCTTGCGCATTCGTTCTAATGGCAATTTAATTGCACCGTGGTATGGTCACATCCTGTCCGGCGAATCCCATGGTCGCATCCTGAAGACCGACCTGAAACGTGGTAGCTGCACGGTACAGTGTCAGACCGAGAAGGGCGGACTCAATACCACCCTGCCATTTCAGAATGTCAGCAAGTACGCGTTCGGCAACTGCTCTAAGTACATCGGGATTAAAAGCCTGAAGCTGGCAGTGGGTCTGCGTAATGTTCCGAGTCGCTCTAGCCGC。
[0015] Furthermore, ClyA and H9N2 AIV HA1 protein were tandemly linked via a linker, and the ribosome binding site was fused to the N-terminus of the ClyA sequence to promote the expression of the fusion protein. A 6×his tag was fused to the C-terminus of the HA1 sequence. The ClyA-HA1 sequence was then inserted between the EcoRI and HindIII restriction sites in the pBAD18-Cm vector using T4 ligase to construct the pBAD18-ClyA-HA1 recombinant plasmid. The ribosome binding site sequence is shown in SEQ ID NO.4.
[0016] Furthermore, the primers for constructing the pBAD18-ClyA-HA1 recombinant plasmid are shown in SEQ ID NO.11~14.
[0017] Furthermore, the vesicle donor is a defective strain of Escherichia coli O78 serotype ΔtolA-ΔaraD; the araD gene of the vesicle donor is knocked out using λ-Red homologous recombination technology.
[0018] Furthermore, the primers for the araD gene knockout targeting fragment are shown in SEQ ID NO.5 and 6.
[0019] Furthermore, the identification primers for the O78 serotype Escherichia coli defective strain ΔtolA-ΔaraD are shown in SEQ ID NO. 7~10.
[0020] The present invention also provides a recombinant biomimetic vesicle prepared by the above method.
[0021] The present invention also provides a recombinant expression vector, pBAD18-Cm optimized by RBS to increase the expression level of the fusion protein ClyA-HA1.
[0022] Furthermore, the RBS sequence is GAAGGAGATATACAT (SEQ ID NO.4).
[0023] The present invention also provides a biomimetic vesicle donor containing the above-mentioned recombinant expression vector.
[0024] Furthermore, the biomimetic vesicle donor knocks out the araD gene using λ-Red homologous recombination technology, eliminating the metabolic degradation of L-arabinose inducer by wild-type Escherichia coli and increasing the stability of the expression of the fusion protein ClyA-HA1.
[0025] This invention also provides a method for presenting recombinant proteins via biomimetic vesicles, which uses high-pressure homogenization technology to rapidly disrupt the bacterial membrane, forcing the release of intracellular fusion proteins and plasma membrane remodeling, thereby effectively driving the bacterial membrane to produce recombinant biomimetic vesicles.
[0026] Furthermore, the pressure of the high-pressure homogenizer is set to 1000 bar and 4°C.
[0027] The present invention also provides the application of the above-described fusion protein, the above-described method, or the above-described recombinant biomimetic vesicles in the preparation of reagents for preventing and treating H9 subtype avian influenza virus and O78 serotype Escherichia coli infection.
[0028] Furthermore, the recombinant biomimetic vesicles are used to inhibit the shedding of H9 subtype avian influenza virus in the chicken's throat and cloaca, reduce the bacterial load in chickens infected with O78 serotype Escherichia coli, and alleviate the degree of inflammation in the air sacs and heart.
[0029] Beneficial effects
[0030] This invention is the first to utilize biomimetic vesicles derived from O78 serotype Escherichia coli to present HA1 protein, which not only increases vesicle production but also enhances the soluble expression of HA1 protein, with low cost and high feasibility. Immunizing SPF chickens with BBVs displaying HA1 protein (BBV-HA1) via nasal drops significantly increased the levels of specific sIgA against H9N2 AIV and outer membrane proteins in the nasal cavity and trachea, significantly increased the levels of IgY against H9N2 AIV and outer membrane proteins in the immune serum, and achieved an HI antibody titer of 5.2 ± 0.84 log2. Furthermore, the in vitro bactericidal activity of the immune serum was significantly enhanced. CD4+ in peripheral blood lymphocytes of immunized chickens... + Enhanced T-cell immune activity. When lymphocytes were stimulated with HA1 and outer membrane proteins respectively, BBV-HA1 showed significantly higher proliferation compared to the PBS group. Immunoprotective results showed that BBV-HA1 effectively reduced bacterial load in chickens, alleviated inflammation in air sacs and the heart, and promoted weight recovery; furthermore, it provided partial protection against H9 subtype virus challenge. The recombinant biomimetic vesicles described in this invention provide effective protection against both H9N2 AIV and O78 serotype APEC, supporting the development of bivalent vaccines. Attached Figure Description
[0031] Figure 1 PCR verification of araD gene knockout in strain J11: A. PCR amplification results using homologous arm primers F1 / R1, M: DL 2000, 1-3 indicate strains that did not successfully mutate, and 4 indicates strains that successfully mutated; B. PCR amplification results using araD gene-specific primers F2 / R2, M: DL 2000, 1-3 indicate strains that did not successfully mutate, and 4 indicates strains that successfully mutated.
[0032] Figure 2 A schematic diagram illustrating the construction of recombinant biomimetic vesicles;
[0033] Figure 3Characterization of recombinant biomimetic vesicles: A. Electron microscopy characterization of recombinant biomimetic vesicles, scale bar 100 nm; B. Particle size characterization of recombinant biomimetic vesicles.
[0034] Figure 4 Results of successful construction of biomimetic vesicle-presented HA1 protein; A. SDS-PAGE analysis of biomimetic vesicle-presented ClyA-HA1 recombinant protein; B. Western Blot identification of biomimetic vesicle-presented ClyA-HA1 recombinant protein; C. Localization analysis of biomimetic vesicle-presented ClyA-HA1 recombinant protein; 1 represents uninduced lysis supernatant, 2 represents induced lysis supernatant, 3 represents BBV-ClyA-HA;
[0035] Figure 5 To determine the amount of protein presented by biomimetic vesicles: A. Total vesicle volume was determined by the BCA method; B. Recombinant protein volume was determined by a BSA gradient concentration method.
[0036] Figure 6 The levels of anti-TX specific sIgA antibodies were measured using the following methods: A. Levels of anti-TX specific sIgA antibodies in the nasal cavity; B. Levels of anti-TX specific sIgA antibodies in the trachea; OD levels were used to measure the levels of anti-TX specific sIgA antibodies. 450 Value representation;
[0037] Figure 7 A. Serum levels of IgY antibodies against TX; OD 450 Value represents; B. HI antibody titer;
[0038] Figure 8 The levels of sIgA antibodies against Omps; A. Levels of anti-TX-specific sIgA antibodies in the nasal cavity; B. Levels of anti-TX-specific sIgA antibodies in the trachea; with OD 450 Value representation;
[0039] Figure 9 A. Serum IgY levels and bactericidal activity against Omps; OD 450 Value indicates; B. bactericidal activity of immune serum;
[0040] Figure 10 Results for lymphocyte proliferation: A. Proliferation results targeting HA1 protein; B. Proliferation results targeting Omps.
[0041] Figure 11 To assess the immune protection of recombinant biomimetic vesicles against chickens infected with serotype O78 APEC, the following factors were considered: A. Body weight changes; B. Pathological changes in the heart and air sacs; C. Lesion score; D. Blood bacterial load; E. Bacterial load in various tissues and organs. Detailed Implementation
[0042] Example 1
[0043] Construction of strains ΔtolA and ΔaraD J11
[0044] The araD gene was knocked out using λ-Red homologous recombination technology. Primers for the targeting fragment (araD-DF / R) were designed based on the E. coli araD gene sequence published in GenBank, and the sequences are shown in Table 1.
[0045]
[0046] Using pKD3 plasmid as a template and araD-DF and araD-DR (Table 1) as primers, the chloramphenicol resistance gene containing the homologous arm was amplified and recovered after identification by 1% gel electrophoresis. Subsequently, the ΔtolA J11 strain carrying pKD46 plasmid was cultured in LB medium supplemented with ampicillin and 0.2% L-arabinose until OD reached 30 °C. 600 = 0.5. Bacterial cells were then collected and washed three times with ice-cold 10% glycerol to prepare electrotransformation competent cells. The targeted DNA fragment was then electrotransformed into the competent cells, and CmR-positive single colonies were screened at 37 ℃. Positive strains were then prepared into electrotransformation competent cells, transformed with the pCP20 plasmid, and cultured at 30 ℃ for 12-16 h. AmR-positive single colonies were picked and screened, and the positive strains were cultured at 42 ℃ to eliminate the pCP20 plasmid, followed by incubation at 37 ℃ to obtain the resistance-free knockout strain ΔtolA ΔaraD J11. PCR identification using primers with homologous arms (F2 / R2) showed that the band size of strain ΔtolA J11 was 797 bp, and the band size of the ΔtolA ΔaraD J11 double-gene mutant was 1122 bp. After the resistance gene was knocked out, using the araD gene-specific primers (F1 / R1), the band size of the ΔtolA J11 strain was 696 bp, and the ΔtolA ΔaraD J11 gene mutant strain did not amplify the araD gene. Figure 1 This indicates that the mutant strain was successfully constructed.
[0047] Example 2
[0048] ΔtolA ΔaraD J11 biomimetic vesicles present H9 subtype AIV HA1 recombinant protein
[0049] Recombinant biomimetic vesicle construction strategies such as Figure 2As shown in Table 2, ClyA (GenBank: AF240780.1) and HA1 (GenBank: JN653620.1) were both synthesized by Nanjing GenScript Biotech Co., Ltd. after codon optimization for E. coli. First, ClyA and HA1 were tandemly linked using Overlap PCR. In primer design, the ribosome binding site (RBS) was fused to the N-terminus of the ClyA sequence to promote fusion protein expression, and a 6×his tag was fused to the C-terminus of the HA1 sequence to facilitate protein expression verification. The ClyA-HA1 sequence was inserted between the EcoRI and HindIII restriction sites in the pBAD18-Cm vector using T4 ligase to construct the pBAD18-ClyA-HA1 recombinant plasmid. Primers are shown in Table 2.
[0050]
[0051] Note: Underlined text indicates enzyme cleavage sites, bold text indicates ribosome binding sites, and italic text indicates 6×his tags.
[0052] The recombinant plasmid pBAD18-ClyA-HA1 was electroporated into ΔtolA ΔaraD J11 competent cells. Then, single clones were randomly selected and cultured in 5 mL of LB medium with shaking at 37 ℃ and 220 rpm for 12 h. The bacterial culture was then identified by PCR. The recombinant plasmids that were correctly identified by PCR were sent to Sangon Biotech for sequencing.
[0053] The ΔtolA ΔaraD J11 strain carrying pBAD18-ClyA-HA1 was inoculated at a 1:100 ratio into chloramphenicol-resistant liquid LB and cultured at 37 °C with shaking at 220 rpm until OD was reached. 600The pH was adjusted to approximately 0.5, and L-arabinose was added to a final concentration of 0.2%. Induction was performed at 25 °C and 220 rpm for 12 h. Bacterial cells were collected and resuspended in PBS. ΔtolA ΔaraD J11 cells expressing the ClyA-HA1 recombinant protein were resuspended in PBS buffer (pH 7.4). BBVs were isolated as follows: Bacterial cell disruption was achieved using an AH-E homogenizer at high pressure (1000 bar, 4 °C). The homogenized sample was collected and centrifuged at 6,000 × g for 30 min at 4 °C to precipitate impurities, and the supernatant was collected. The supernatant was filtered through a 0.45 μm filter and concentrated using a 100 kDa ultrafiltration tube. Then, ultracentrifugation (150,000 g, 1 h, 4 °C) was performed, and the precipitate was resuspended in sterile PBS (pH 7.4) to obtain the enriched biomimetic vesicles. We performed electron microscopy and particle size analysis on the isolated BBVs and BBV-ClyA-HA1. Transmission electron microscopy (TEM) analysis of the self-assembly of BBVs revealed that the recombinant BBVs maintained a nanoscale spherical structure, indicating that the expression of the recombinant ClyA-HA1 protein did not affect the morphology of the BBVs. Particle size analysis using a Malvern particle analyzer (ES90 Nano) showed that the particle size of BBV was 205.77 ± 1.76 nm, while the particle size of BBV-ClyA-HA1 was 233.70 ± 3.99 nm. Figure 3 ).
[0054] Subsequently, SDS-PAGE electrophoresis was performed. The results showed that, compared with the uninduced bacterial culture, both the supernatant and BBVs contained an overexpression band of approximately 70 kDa. Figure 4 A). Western blotting using H9N2 AIV TX polyclonal antibody serum as the primary antibody showed a specific band of approximately 70 kDa in the supernatant and BBVs after induction. Figure 4 B), consistent with the theoretical molecular weight of ClyA-HA1, confirms that the recombinant protein is correctly expressed in the supernatant and BBVs. Furthermore, we attempted to determine the localization of the recombinant protein in BBVs. BBVs expressing the ClyA-HA1 recombinant protein were incubated with proteinase K at 37 °C with or without 1% SDS. Western blot analysis was then performed using 6×His monoclonal antibody as the primary antibody. The data showed that proteinase K directly degraded the ClyA-HA1 protein regardless of whether the BBV structure was disrupted by SDS, indicating that the HA1 protein is localized on the surface of BBVs (B). Figure 4 C).
[0055] The total protein content of outer membrane vesicles and biomimetic vesicles was determined using the BCA method. It was found that naturally occurring outer membrane vesicles contained 2.24 mg per 1 L of culture, while biomimetic vesicles contained 9.66 mg. Furthermore, the amount of recombinant protein was preliminarily estimated using the Coomassie brilliant blue method. SDS-PAGE analysis of biomimetic vesicles with known concentrations of bovine serum albumin (BSA) standards was performed, and the samples were stained with Coomassie brilliant blue. Based on the gray values of the BSA protein bands, the recombinant protein loading in the biomimetic vesicles was preliminarily analyzed. It was found that each 9.66 mg biomimetic vesicle contained 3.26 mg of recombinant protein, representing 33.74% of the total content of the biomimetic vesicles. Figure 5 ).
[0056] Example 3
[0057] Immunoprotective assay of recombinant biomimetic vesicles
[0058] One-week-old SPF chickens were randomly divided into 9 groups. H9N2 AIV TX was inactivated with formaldehyde at a final concentration of 2‰ for 24 hours at 4℃, and Escherichia coli J11 strain was heat-inactivated for later use. The immunization groups are shown in Table 3. The TX inactivated vaccine and J11 inactivated vaccine were mixed with adjuvant at a 1:1 ratio and administered via subcutaneous injection at multiple sites, with immunizations every two weeks for a total of two immunizations. The BBV, HA1, BBV+HA1, and BBV-HA1 groups were immunized via nasal drops, with immunizations every week for a total of three immunizations.
[0059]
[0060] The levels of specific IgY antibodies against Omps and TX in serum and specific sIgA antibodies against nasal and tracheal lavage fluid were determined using an indirect ELISA method. Briefly, the ELISA plate was incubated overnight at 4 °C with 50 ng of purified whole Omps or TX virus in 100 μL of coating buffer (15.9 mM Na2CO3, 29.7 mM NaHCO3, pH 9.6). The plate was then washed three times for 10 min each time with phosphate-buffered saline (PBST) containing 0.05% Tween-20. The plate was blocked with PBST containing 5% skim milk at 37 °C for 2 h. Serum samples were diluted 1:6400, and nasal and tracheal lavage fluid were diluted 1:5. 100 μL of the diluted sample was added to each well, and the plates were incubated at 37 °C for 1 h. Then, add 100 μL of rabbit anti-chicken IgY-HRP(H+L) or rabbit anti-chicken sIgA-HRP(H+L) antibody (1:8000 dilution) and incubate at 37 ℃ for 1 h. Add 100 μL of TMB and react in the dark for 15 min, then add 50 μL of 2M H2SO4 to terminate the reaction. Finally, measure the OD using a microplate reader. 450 The optical density value at nm.
[0061] Assay for HI antibody levels in immune serum: Based on the HA test results of the TX strain, 4 units of antigen were prepared. Using a 96-well V-shaped microplate, 25 μL of PBS was added to wells 1-11, and 50 μL of PBS was added to well 12. 25 μL of the serum to be tested was added to well 1, and after thorough mixing, 25 μL was transferred to well 2. This process was repeated serially until well 10 was reached. 25 μL of the diluted antigen was discarded from well 10. Well 11 was used as a virus control, and well 12 as a red blood cell control. 25 μL of 4 units of antigen was added to wells 1-11, and the plate was gently tapped to mix. The plate was incubated at 37 °C for 15 min. Then, 25 μL of 1% chicken red blood cell suspension was added to each well from right to left. The plate was gently shaken on a microplate shaker and incubated at 37 °C for 15 min. The results were observed when red blood cells showed clear precipitation in the red blood cell control wells.
[0062] To determine the bactericidal activity of antibodies in serum samples in vitro, we employed a modified serum bactericidal activity assay. The APEC O78 strain was cultured to the logarithmic growth phase and then resuspended in PBS to a concentration of 10. 6 CFU / mL was used for subsequent assays. The immune serum was diluted 1:10 with LB medium. In a round-bottom 96-well plate, 90 μL of diluted serum was mixed with 10 μL of prepared bacteria and incubated with shaking at 37 °C and 100 rpm for 1 h. The reaction mixture was serially diluted 10-fold and incubated overnight at 37 °C to count viable colonies. To calculate the survival rate of O78 in different serum samples, the number of serum-treated bacteria was divided by the number of original bacteria. All serum samples were tested independently three times.
[0063] 3.1 Evaluation of mucosal immunity against H9N2 AIV after vaccination
[0064] One week after each immunization, nasal and tracheal lavage fluid from chickens was collected. The levels of vaccine-induced TX-specific sIgA antibodies against TX were measured using an indirect ELISA method with purified H9N2 AIV TX. Results showed that after the first and second immunizations, no high levels of sIgA antibodies were observed in the trachea and nasal cavity of immunized chickens in any group. After the third booster immunization, antibody levels in the nasal cavity and trachea of the BBV-HA1 immunized group were significantly higher than those in the PBS group, while there were no significant differences in antibody levels between the inactivated vaccine group (TX-inactive) and other immunized groups and the PBS group. Figure 6 This indicates that only by using BBV as a carrier to present HA1 protein can the body's mucosal immune response be stimulated, inducing the body to produce specific mucosal immunity against H9N2 AIV TX.
[0065] 3.2 Evaluation of humoral immunity against H9N2 AIV after vaccination
[0066] One week after each immunization, blood was collected from chickens and serum was separated. Humoral immune responses to H9N2 AIV TX were measured in each immunization group using indirect ELISA and HI assays. Indirect ELISA results showed that one week after the first immunization, serum IgY antibody levels in all immunized chicken groups did not increase. One week after the second booster immunization, only the TX-inactive immunization group showed a significant increase in IgY antibody levels. One week after the third immunization, serum IgY levels in both the TX-inactive and BBV-HA1 immunization groups increased significantly. HI assay results showed that one week after the first immunization, HI antibody levels in the TX-inactive immunization group increased, averaging 2.4 ± 1.52 log2. One week after the second booster immunization, the HI antibody titer in the BBV-HA1 immunization group increased slightly, reaching 2 log2, while the HI antibody titer in the TX-inactive immunization group increased significantly, reaching 8.6 ± 0.86 log2. One week after the third immunization, the titers of HI antibodies against TX-inactive, BBV+HA1, and BBV-HA1 all increased significantly, with BBV+HA1 reaching 3±0.71 log2, BBV-HA1 reaching 5.2±0.84 log2, and TX-inactive reaching 10.8±0.45 log2. Figure 7 Besides the TX-inactive immunization group, which induced the highest antibody levels, the BBV-HA1 immunization group also effectively stimulated the body to produce high antibody levels. However, the antibody levels produced by immunization with HA1 protein alone or with BBV as an adjuvant for HA1 protein were significantly lower than those produced by BBV-HA1. This indicates that HA1 protein presented by BBV has enhanced immunogenicity, allowing it to be better recognized by the body and thus generating a stronger specific humoral immune response.
[0067] 3.3 Evaluation of mucosal immunity following vaccination against APEC
[0068] One week after each immunization, nasal and tracheal lavage fluids from chickens were collected. The levels of vaccine-induced APEC-specific sIgA antibodies were measured using an indirect ELISA method with purified Omps protein. Results showed that after the first immunization, no high levels of sIgA antibodies were observed in the trachea and nasal cavity of any group of immunized chickens. After the second booster immunization, antibody levels for BBV, BBV+HA1, and BBV-HA1 increased. After the third booster immunization, antibody levels for BBV, BBV+HA1, and BBV-HA1 further increased, showing significant differences compared to the PBS group. However, antibody levels in the HA1 and J11-inactive groups did not differ significantly from the PBS group. Figure 8 This indicates that BBV can induce the body to produce specific mucosal immunity against APECOmps.
[0069] 3.4 Evaluation of humoral immunity against APEC after vaccination
[0070] One week after each immunization, blood was collected from chickens and serum was separated. Humoral immune responses to APEC were measured in each immunization group using indirect ELISA and serum bactericidal assays. Results showed that after the first immunization, serum IgY antibody levels in all immunized chicken groups did not increase. After the second and third booster immunizations, anti-Omps IgY antibody levels significantly increased in the J11-inactive, BBV, BBV+HA1, and BBV-HA1 immunization groups, showing significant differences compared to the PBS and HA1 immunization groups. The J11-inactive group had the highest antibody level, while there were no significant differences among the BBV, BBV+HA1, and BBV-HA1 immunization groups. Figure 9 A). In addition, we tested the bactericidal activity of each group of immune sera. Freshly isolated immune sera were incubated with APEC in vitro, cultured at 37 °C with shaking for 1 h, then diluted and plated, and the number of surviving colonies was counted. The results showed that after the third booster immunization, BBV, BBV+HA1, BBV-HA1, and J11-inactive immune sera effectively inhibited bacterial survival, while PBS and HA1 immune sera failed to inhibit bacterial survival. Figure 9 B). This indicates that BBVs can effectively stimulate the body's specific humoral immune response and produce specific antibodies against APEC.
[0071] 3.5 PBMC cell proliferation
[0072] After three immunizations, we isolated PMBCs from chickens and stimulated lymphocytes with HA1 and Omps proteins, respectively. Cell proliferation was assessed using the CCK-8 assay. Specifically: After PMBC isolation and counting, cells were cultured in RPMI 1640 medium containing 10% FBS at a density of 10 μL per well.6 Cells were seeded into 96-well plates and stimulated with Omps (20 μg / well) and cultured at 37 °C with 5% CO2 for 48 h. 10 μL of CCK-8 solution was added to each well and incubated at 37 °C in the dark for 1 h. The optical density (OD) was then measured at 450 nm using a microplate reader. 450 The Stimulation Index (SI) is calculated as the OD of cells stimulated by Opps. 450 Value / OD of unstimulated cells 450 The results showed that after stimulation with HA1 protein, the HA1, BBV+HA1, BBV-HA1, and TX inactivated vaccine groups showed extremely significant proliferation compared with the PBS group (p≤0.01), with the BBV-HA1 group having the highest lymphocyte proliferation index. Figure 10 A); Under Omps protein stimulation, the BBV, BBV+HA1, BBV-HA1, and J11 inactivated vaccine groups showed extremely significant proliferation compared to the PBS group (p≤0.01). Figure 10 B).
[0073] Example 4
[0074] Results of the challenge protection test
[0075] 4.1 Protection against H9N2 attack
[0076] Following the immunization program described above, SPF chickens were challenged with H9N2 AIV TX via nasal drops. Laryngeal and cloacal swabs were collected on days 3, 5, and 7 post-challenge. The effectiveness of the vaccine in protecting SPF chickens from H9N2 AIV challenge was determined using real-time quantitative RT-PCR based on the M gene-based H9N2 AIV probe method previously established in our laboratory. Specifically, primers and probes were designed and analyzed using Primer 5.0 and Lasergene 7.1 software, and synthesized by Sangon Biotech (Shanghai) Co., Ltd. The primers are shown in Table 4.
[0077]
[0078] To accurately determine the virus shedding status of chickens, cDNA was extracted from collected laryngeal and cloacal swabs and absolute quantitative PCR was performed according to the following system: 10 μL of 2×PerfectStart IIProbe qPCR SuperMix UDG, 0.4 μL of 10 μM forward and reverse primers, 0.4 μL of probe, and 2 μL of reverse transcription product were added to a total volume of 20 μL. Finally, 6.8 μL of ddH2O was added to complete the system.
[0079] The reaction conditions were set as follows: pre-denaturation at 94 °C for 5 min; denaturation at 94 °C for 5 seconds; annealing at 60 °C for 30 seconds; fluorescence signal was collected at the end of annealing; and 40 cycles were performed.
[0080] The results showed that no cloacal shedding was detected in any of the SPF chickens at 3, 5, and 7 days post-challenge, while laryngeal shedding varied. The TX inactivated vaccine group completely suppressed laryngeal shedding (0 / 8), while the other immunization groups failed to completely suppress it. The BBV-HA1 group showed the best protective effect, with only 2 chickens shedding the virus in their larynx on day 7. Immunization with HA1 protein alone still resulted in 5 chickens shedding the virus in their larynx, as did 5 chickens in both the BBV and BBV+HA1 groups. These results indicate that HA1 protein presentation to BBV provides better immunoprotection (Table 5).
[0081]
[0082] 4.2 Challenge protection against APEC serotype O78
[0083] SPF chickens were immunized according to the above immunization program, and then treated with O78 serotype APEC (10 7 SPF chickens were challenged with CFU / chicken via air sac injection and observed for 7 days. To evaluate the effect of immunization on the weight gain of SPF chickens after challenge, chickens in each group were weighed daily. The results showed that the weight of SPF chickens in each group decreased continuously within 4 days after challenge, and then gradually increased starting from day 5. Compared with the Blank healthy control group, the weight differences among SPF chickens in the BBV, BBV+HA1, BBV-HA1, and J11 inactivated vaccine groups disappeared on day 7 after challenge (p>0.05), while the weight of SPF chickens in the PBS and HA1 groups was still significantly different from that in the Blank group (p<0.001). Figure 11 A).
[0084] To evaluate the effect of immunization on infection in SPF chickens after challenge, chickens were euthanized 7 days post-challenge, and the lesions of the heart and air sacs were recorded and analyzed, with lesion scores assigned. Results showed that chickens in the PBS and HA1 groups had underdeveloped hearts, thickened pericardium with abundant fibrinous exudate, and thickened and turbid air sacs. However, there were no significant differences in the heart and air sacs between the BBV, BBV+HA1, BBV-HA1, and J11 inactivated vaccine groups and the Blank group. Figure 11 B,C).
[0085] In addition, we evaluated the dynamic distribution and content of bacteria in SPF chickens. Three chickens from each group were randomly euthanized 24 h after bacterial challenge, and liver, spleen, lung, and kidney tissues were collected. Colony counts were performed after homogenization with sterile PBS. Blood samples were also collected at 24 h and 96 h post-challenge for bacterial load determination. The samples were serially diluted 10-fold in sterile PBS and plated onto MacConkey agar for colony count. Colony counts showed that, compared to the PBS group, the bacterial load in the blood of chickens immunized with BBV, BBV+HA1, BBV-HA1, and J11 inactivated vaccines was significantly lower at 72 h post-challenge (p < 0.05). Except for the trachea, the bacterial load in the liver, spleen, lung, and kidney of chickens immunized with BBV, BBV+HA1, BBV-HA1, and J11 inactivated vaccines was significantly lower than that in the PBS group (p < 0.05). Figure 11 D,E).
Claims
1. A fusion protein, wherein the fusion protein is obtained by linking a ClyA protein and an HA1 protein together via a linker from the N-terminus to the C-terminus; the nucleotide sequences encoding the ClyA protein, the linker and the HA1 protein are shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.
3.
2. A method for preparing biomimetic vesicles of *Escherichia coli* that present the HA1 protein of H9 subtype avian influenza virus, characterized in that, ClyA and H9N2 AIV HA1 proteins were linked together via a linker to express a fusion protein in a vesicle donor. High-pressure homogenization was used to present the ClyA-HA1 fusion protein onto the surface of biomimetic vesicles, resulting in recombinant biomimetic vesicles. ClyA is located at the N-terminus of the H9N2 AIV HA1 protein. The nucleotide sequences encoding the ClyA protein, the linker, and the HA1 protein are shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.
3. The vesicle donor was O78 serotype Escherichia coli Δ... tolA- Δ araD .
3. The method for preparing Escherichia coli biomimetic vesicles that present H9 subtype avian influenza virus HA1 protein according to claim 2, characterized in that, The vesicle donor knocked out the araD gene using λ-Red homologous recombination technology.
4. The method for preparing Escherichia coli biomimetic vesicles that present H9 subtype avian influenza virus HA1 protein according to claim 3, characterized in that, Primers for the araD gene knockout targeting fragment are shown in SEQ ID NO.5 and 6.
5. The method for preparing Escherichia coli biomimetic vesicles that present H9 subtype avian influenza virus HA1 protein according to claim 3, characterized in that, The O78 serological type Escherichia coli defective bacteria Δ tolA- Δ araD The identification primers are shown in SEQ ID NO. 7~10.
6. A recombinant biomimetic vesicle, characterized in that, It is prepared by the method described in any one of claims 2 to 5.
7. The application of the recombinant biomimetic vesicles according to claim 6 in the preparation of reagents for preventing and treating H9N2 subtype avian influenza virus and O78 serotype Escherichia coli infection.
8. The application according to claim 7, characterized in that, The recombinant biomimetic vesicles are used to inhibit the shedding of H9N2 subtype avian influenza virus in the chicken throat and reduce the bacterial load in chickens infected with O78 serotype Escherichia coli, thereby alleviating the degree of inflammation in the air sacs and heart.
Citation Information
Patent Citations
Novel vaccine form for submitting heterologous protein to surface of escherichia coli outer membrane vesicles
CN105861402A
Live bacterial vaccines for viral infection prophylaxis or treatment
WO2008039408A2
